Loading...
XNAS
STAA
Market cap1.11bUSD
Oct 08, Last price  
22.38USD
1D
0.09%
1Q
-19.38%
Jan 2017
106.27%
Name

STAAR Surgical Co

Chart & performance

D1W1MN
XNAS:STAA chart
P/E
—
P/S
4.65
EPS
—
Div yield, %
—
Shrs. gr., 5y
0.66%
Rev. gr., 5y
7.93%
Revenues
239m
-23.72%
56,282,00059,363,00074,894,00075,345,00054,958,00062,765,00063,783,00072,215,00074,987,00077,123,00082,432,00090,611,000123,954,000150,185,000163,460,000230,472,000284,391,000322,415,000313,901,000239,442,000
Net income
-80m
L+298.10%
-15,044,000-15,999,000-23,195,000-6,200,00053,0001,348,000-1,763,000398,000-8,392,000-6,533,000-12,129,000-2,139,0004,968,00014,048,0005,913,00027,511,00039,665,00021,347,000-20,208,000-80,448,000
CFO
-34m
L
-8,647,000-11,184,000-8,228,0001,427,000-4,417,0005,346,0003,217,0003,352,000-7,951,000-2,162,0001,049,0002,853,00012,767,00025,795,00020,951,00043,962,00035,715,00014,594,00015,725,000-34,230,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

STAAR Surgical Company, along with its subsidiaries, specializes in ophthalmological solutions, focusing on the design, development, manufacturing, and commercialization of implantable lenses for vision correction, complete with the sophisticated delivery systems necessary for their implantation. A core offering is the Visian implantable Collamer lens (ICL) product line, designed to correct various visual impairments including myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia (age-related loss of near vision). Specifically, their Hyperopic ICL addresses farsightedness. Furthermore, STAAR Surgical provides preloaded silicone intraocular lenses and associated injector systems, crucial for cataract surgery. The company also sells various injector components and ancillary medical instruments and devices. Its market outreach extends to a diverse array of healthcare providers, such as ophthalmic surgeons, specialized vision and surgical centers, hospitals, governmental healthcare facilities, and distributors. These products are predominantly utilized by ophthalmologists. Sales are conducted directly via its own sales force in key countries like the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore. In other significant markets, including China, Korea, India, France, the Benelux region, Italy, and other international territories, the company employs a hybrid sales model, leveraging both its direct representatives and independent distributors. Founded in 1982, STAAR Surgical Company is headquartered in Lake Forest, California.

Key people

Louis E. Silverman
Independent Chairman of the Board · since 2017
Caren L. Mason
President, Chief Executive Officer, Director · since 2015
Hans-Martin Blickensdoerfer
Senior Vice President - Commercial Operations, Direct Markets Europe and China · since 2017
James E. Francese
Senior Vice President - Commercial Operations, North American and APAC · since 2016
Graydon Hansen
Senior Vice President - Global Operations · since 2017
Chief Financial Officer, Vice President · since 2017
Jon K. Hayashida
Vice President - Global Clinical and Medical Affairs · since 2015
Philippe Subrin
Vice President, Collamer Lens Manufacturing and General Manager, Nidau Operations · since 2017
Denise McEachern
Global Head - Regulatory Affairs and Quality Assurance · since 2014
Samuel J. Gesten
Chief Legal Officer, Corporate Secretary · since 2017
Independent Director · since 2016
John C. Moore
Independent Director · since 2008
IPO date
Feb 24, 1992
Employees
882
Domiciled in
US
Incorporated in
US
Legal address
c/o Corporation Service Company, 251 Little Service Company
Wilmington, DE 19808
US
Headquarters
1911 Walker Avenue
Monrovia, CA 91016
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑002024‑122023‑122022‑122021‑122021‑002020‑002018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT